LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.04
−2.34%Year over year
Reported trailing growth
- Revenue
- -55.0%
- EBITDA
- -22.7%
- EBIT
- +46.1%
- EPS
- —
- Free cash flow
- +22.1%
- Operating cash flow
- +22.3%
Forward estimates
Based on analyst estimates
- Revenue
- +2.1%
- EBITDA
- +19.8%
- EPS
- +46.8%
Three-year CAGR
- Revenue
- -92.5%
- EBITDA
- -31.0%
- EBIT
- +43.2%
- Net income
- +20.0%
- EPS
- —
- Free cash flow
- +7.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026